Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01422369 · ClinicalTrials.gov registry record · Phase 4
Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin
A Phase 4 study, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT01422369 is a Phase 4 study that has completed, run by Kowa Research Institute. The registered enrollment target is 28 participants.
The verdict
NCT01422369, a Phase 4 study, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a Phase 4, single center, open label, fixed-sequence, multiple dose, 2-way drug-drug interaction study.
Interventions
- DRUG Pitavastatin (NK-104)
- DRUG Darunavir/Ritonavir (Prezista)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01422369
The ClinicalTrials.gov registry entry for NCT01422369 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pitavastatin (NK-104) is the first listed.
NCT01422369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01422369 about?
NCT01422369 is a clinical study titled "Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin". This is a Phase 4, single center, open label, fixed-sequence, multiple dose, 2-way drug-drug interaction study.
What is the current status of trial NCT01422369?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2011-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01422369?
The interventions under investigation include: Pitavastatin (NK-104) (DRUG), Darunavir/Ritonavir (Prezista) (DRUG).
Who is sponsoring clinical trial NCT01422369?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.